Lipase elevation on admission predicts worse clinical outcomes in patients with COVID-19.

ABSTRACT:

Background and objectives

Hyperlipasemia is highly prevalent among coronavirus disease 2019 (COVID-19) patients. The aim of this study was to assess the effect of lipase activity, measured at the time of admission, on the clinical course and mortality in COVID-19 patients.

Methods

The population of this study comprised 12,139 patients who were hospitalized due to COVID-19 between June 2020 and June 2021 in a pandemic hospital. Of these, 8819 patients were excluded from the study due to missing data, four patients were excluded due to a diagnosis of acute pancreatitis (according to the revised Atlanta criteria), and 72 patients were excluded due to alcohol use or having a history of chronic pancreatitis. The final study sample consisted of the remaining 3244 COVID-19 patients

SUBMITTER: Kiyak M 

PROVIDER: S-EPMC9054729 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature